中药ETF(159647)周线冲击五连阳，夏荔芪胶囊获批首家中药二级保护品种

Group 1 - The Chinese traditional medicine index (930641) has shown a slight increase of 0.20% as of July 25, 2025, with notable gains from companies such as Zhenbao Island (603567) up 5.92% and Fangsheng Pharmaceutical (603998) up 1.67% [1] - The Chinese traditional medicine ETF (159647) has increased by 0.19%, with a recent price of 1.03 yuan and a one-month growth of 5.56% [1] - The National Medical Products Administration has approved the first secondary protection variety of traditional Chinese medicine, the Xia Liqi Capsule from Shijiazhuang Yiling Pharmaceutical Co., with a protection period of seven years [1] Group 2 - Chinese innovative drug companies are transitioning from quantitative to qualitative changes, with expectations of significant business development (BD) transactions in the coming years, leading to potential mergers and acquisitions [2] - The next 5 to 10 years are anticipated to be a period of explosive growth for Chinese innovative drugs, with domestic companies expected to emerge as globally competitive multinational corporations (MNCs) [2] - The traditional Chinese medicine ETF closely tracks the traditional Chinese medicine index, which reflects the overall performance of listed companies involved in the production and sales of traditional Chinese medicine [2] Group 3 - As of June 30, 2025, the top ten weighted stocks in the traditional Chinese medicine index account for 55.96% of the index, including companies like Pian Zai Huang (600436) and Yunnan Baiyao (000538) [3]